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Abstract
The Antarctic region is of particular interest to natural products chemists because it
remains relatively unexplored and possesses a wealth of unique biodiversity. Organisms that
thrive in this region must produce different chemical defenses to survive in the harsh polar
environment, making their secondary metabolites original and potentially useful as drugs for
human disease. These compounds often have very complex structures, making their syntheses
difficult and impractical. With this knowledge, five Antarctic marine invertebrates were
extracted in search of their secondary metabolites. The chemical isolation studies were
performed by macroorganism solvent extraction followed by chromatographic separation and
purification of metabolites guided by proton nuclear magnetic resonance spectroscopy. The
isolates were screened in malaria, leishmaniasis, and cytotoxicity bioassays. Based on the
bioassay data, an extract of interest was chromatographed by high performance liquid
chromatography and analyzed by liquid chromatography-mass spectrometry. Potential pure
compounds could not be further isolated or characterized due to an insufficient quantity.
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Introduction

Pharmacognosy is a field of science devoted to the search for new drugs from natural
sources, along with the study of the physical, chemical, biochemical, and biological properties of
drugs, as defined by the American Society of Pharmacognosy.1 Humans have been combating
disease for thousands of years. Before the days of pharmaceutical development, societies cured
diseases using the elements of their natural environments. Knowledge of which plants healed
specific ailments was accumulated over years by a mixture of trial and error and mere chance.
Therefore, it is not surprising that many of the pharmaceutical drugs on the market today are
derived from natural products, or chemicals that are produced by living organisms, including
plants, animals, fungi, and bacteria. Many of these chemicals exhibit biological activity that
makes them ideal candidates for drug discovery and development. In fact, over 60% of cancer
drugs and 75% of infectious disease drugs are developed from natural products.2 The percentage
is even greater for specific indications. For example, 78% of antibacterial and 74% of anticancer
compounds originate from natural products.3 Some that are currently in medicinal use include
penicillins (antibiotics), morphine (an analgesic), and paclitaxel (the anticancer drug taxol).4

Figure 1 Left to right: penicillin core structure, morphine, paclitaxel.
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With the advent of new technologies, the focus in drug discovery has shifted toward
combinatorial chemistry and virtual screening of drug-target interactions.3,
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However, the

available drug libraries are limited to known compounds and by the human imagination. There is
also much greater diversity among natural products than combinatorial molecules. As a result,
compounds in combinatorial libraries occupy a smaller volume of chemical space, the space
spanned by all combinations of nuclei in all topology isomers, than either natural products or
drugs.3, 6

Figure 2 Plots representing the volume of chemical space occupied by a) combinatorial compounds, b) natural
products, and c) drugs6. Combinatorial molecules occupy a defined region of this space, while natural products and
drugs occupy this same space as well as a larger volume. There is obvious overlap between the diversity of natural
products and drugs.

In traditional natural products isolation, the resulting isolate often has a complex structure
that would be difficult and impractical to synthesize. Characterization of these molecules aids in
the discovery of therapeutic mechanisms of action and biosynthetic pathways and also provides a
5

foundation for developing natural product analogs.7 Medicinal chemistry is generally governed
by Lipinski’s Rule of Five, which is used to identify small molecules that are likely to possess
desirable pharmacokinetic properties. The criteria for these molecules are that they have no more
than five hydrogen bond donors, no more than ten hydrogen bond acceptors, a molecular weight
less than 500 daltons, and a log P less than five. However, many important natural products
violate this rule, as their molecular weights often exceed 500 daltons.7 One such molecule is
palmerolide A, which is a macrocyclic polyketide isolated from the Antarctic tunicate Synoicum
adareanum that exhibits activity against melanoma by inhibiting vacuolar ATPase.8 Another
similar class of polyketides is the chrondropsins, which have been isolated from a number of
marine sponges including Ircinia ramosa9 and Chondropsis sp.10 Like palmerolide A, these
molecules inhibit vacuolar ATPases.11

Figure 3 The top is palmerolide A and the bottom is the chondropsin backbone.
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The ocean comprises approximately seventy percent of the earth’s surface.
Consequentially, the number of marine organisms greatly exceeds the number of terrestrial
organisms. The biodiversity of the marine environment is so great that it has become one of the
focuses of a number of scientific disciplines over the past few decades. The majority of the
ocean’s organisms thrive on the interface between land and sea, which constitutes less than one
percent of the earth’s surface.12 As a result, there is great competition among these species for
food and space, especially in the case of sessile organisms such as coral, sponges, and tunicates.
In response to this, many species have developed chemical mechanisms to defend
themselves.12 These chemical defenses are secondary metabolites, which are often terpenoids,
alkaloids, polyketides, peptides, sugars, and steroids.12 In many cases, these molecules exhibit
activity against an array of human diseases. In the past, secondary metabolites were thought to be
waste products and were disregarded, but their importance in drug discovery has recently been
recognized.13 So far, there have been more than 16,000 natural products isolated from marine
organisms,14 which have proven to yield large quantities of chemically diverse and biologically
active molecules.15 For instance, prostaglandins, which are used as non-steroidal antiinflammatory drugs (NSAIDs), were first reported in high yields from Plexaura homomalla, a
Caribbean gorgonean.14 Another important class of compounds is the statins, which have been
isolated from a number of fungi.4, 15

Figure 4 On the left is prostaglandin E1 (PGE1); on the right is lovostatin
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The Polar Regions have surprisingly great biodiversity unique to their climate, but these
habitats are among the least explored due to their lack of accessibility. As a result, the
ecosystems have remained relatively undisturbed and uninfluenced by humans. In addition, the
Antarctic has been isolated for 25 million years by the Circumantarctic Current.16 Organisms that
thrive in these harsh, cold environments are of interest because their chemical ecology may differ
significantly from organisms in warmer climates. Therefore, their secondary metabolites are
particularly appealing because they are exclusive to species of the Polar Regions. The benthos of
Antarctica is unique in that up to 55% of the ocean floor is covered in a variety of sponges16,
which are often the dominant organisms as a result.17 Five sessile Antarctic marine invertebrates
were investigated in an attempt to identify novel secondary metabolites. Separations were
performed using a variety of chromatography techniques in conjunction with proton nuclear
magnetic resonance spectroscopy and bioassays to guide the isolation. Additional studies remain
in order to obtain enough isolate for thorough purification and structure elucidation.
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Experimental Methods

Five Antarctic marine invertebrates were extracted for analysis. An orange-top sponge
with yellow interior (PSC01-53, 240 g freeze-dried), a calcaneus bryozoan (PSC03-133, 300 g
freeze-dried), and a dock finger sponge (PSC08-01, 1.42 kg freeze-dried) were collected by
SCUBA by the Baker research group from the waters surrounding Palmer Station, Antarctica in
2001, 2003, and 2008, respectively. Isodictya setifera (LMGSC10-108, 120 g freeze-dried) and
Didemnum sp. (LMGSC10-96, 120 g freeze-dried) were collected by trawling by the Baker
research group from Low Island, Antarctica in 2010. The five lyophilized samples were
exhaustively extracted in 1:1 CH3OH and CH2Cl2. The organisms were then allowed to dry for
twenty-four hours before being similarly extracted in 1:1 CH3OH and H2O (Appendix A). Proton
nuclear magnetic resonance (1H NMR) spectra were obtained for each extract (Appendix B).
The lipophilic extract (50% CH2Cl:CH3OH) of each organism was chromatographed by
normal phase medium pressure liquid chromatography (MPLC) using a solvent gradient of 100%
hexane to 100% EtOAc (Appendix C). All fractions collected were then dissolved in dimethyl
sulfoxide (DMSO) at a concentration of 2 mg/mL. Aliquots of 200 µL of each fraction were
transferred to a 96-well plate, which was submitted to Dr. Dennis Kyle for malaria testing with
Plasmodium falciparum 3D7, cytotoxicity testing using the A549 cell line, and leishmaniasis
testing against Leishmania donovani.
Based on the results of the bioassay, the malaria hit (LMGSC10-108-6-7) was dissolved
in 50% CH3CN:CH3OH in preparation for a reverse phase MPLC wet injection. However, the
sample was not completely soluble, so it was chromatographed in two separate experiments
using the dry, insoluble portion of the sample and the liquid extract. Both samples were
9

chromatographed with a 30-g Teledyne Isco RediSep Gold High Performance C18 column using
a solvent gradient of 10% H2O:CH3CN to 100% CH3CN, followed by a 100% CH3OH wash at a
flow rate of 35 mL/min (Appendix C). Both injections yielded five fractions each, which were
analyzed by 1H NMR in deuterated methanol (CD3OD).
Liquid chromatography-mass spectrometry (LC-MS) data was obtained for fraction 4
(LMGSC10-108-6-7-4b) of the CH3CN:CH3OH extract to determine an appropriate solvent
gradient and absorption wavelengths since the compound did not absorb at 254 nm. This fraction
was then chromatographed by reverse phase high performance liquid chromatography on a 4.6 x
250 mm Phenomenex Luna C18 5μ column using a solvent gradient of 10% H2O:CH3CN to
100% CH3CN with 210- and 225-nm detection, yielding 13 fractions (Appendix C). 1H NMR
spectra were obtained for each fraction in deuterated dimethyl sulfoxide (DMSO-d6).
Fraction 11 (LMGSC10-108-6-7-4b-11, 0.8 mg) was dissolved in CH3OH and submitted
for LC-MS to determine the purity of the sample, although the quantity of sample material was
insufficient for additional purification (Appendix C).
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Results and Discussion

Five Antarctic marine invertebrates were extracted in organic solvents. The lipophilic
extract (50% CH2Cl2:CH3OH) of each organism was chromatographed by normal phase MPLC
and the resulting fractions were submitted for malaria, leishmaniasis, and cytotoxicity bioassays
(Appendix D). Eleven fractions exhibited mild antimalarial activity with little cytotoxicity
(secondary interests, partial hits) and one fraction, LMGSC10-108-6-7, exhibited moderate
antimalarial activity with low cytotoxicity (primary interest, hit). None of the fractions submitted
exhibited activity against leishmaniasis. Although the isolation could not be fully guided by
bioassay in the interest of time, the fractions generated from the separation of the antimalarial hit
will be submitted for bioassay.
The antimalarial hit, LMGSC10-108-6-7, was further chromatographed by reverse phase
MPLC. A fraction of interest, identified by its 1H NMR spectrum, was separated by reverse
phase HPLC. A fraction of interest was again identified using 1H NMR, which revealed the
presence of an aromatic ring. LC-MS data was obtained, indicating that the sample is a mixture
of components; however, the mass of the sample is insufficient for further purification.
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Appendix A: Fractionation Schemes
Orange-top sponge,
yellow interior
(PSC01-53)
240 g

Silica column (80 g)
100% hexane to 100% EtOAc

50% CH3OH:CH2Cl2 (-6)

50% H2O:CH3OH (-7)

16.5 g

45.0 g

Fraction 1a*

Fraction 1b

18.6 mg

4.4 mg

Fraction 2a

Fraction 2b*

153 mg

642 mg

Fraction 3a

Fraction 3b

638 mg

109 mg

Fraction 4a

Fraction 4b

151 mg

243 mg

Fraction 5a*

Fraction 5b

71.6 mg

32.3 mg

Fraction 6a

Fraction 6b*

24.2 mg

9.6 mg

Fraction 7a

Fraction 7b

15.8 mg

19.2 mg

Fraction 8a

Fraction 8b

194 mg

252 mg

Fraction 9a

Fraction 9b

306 mg

2.11 g

Fraction 10a

Fraction 10b

1.23 g

947 mg

Fraction 11a
773 mg
Fraction 12a
676 mg
Fraction 13a

* Indicates fractions that
exhibited antimalarial activity

2.51 g
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calcaneus bryozoan
(PSC03-133)
300 g

Silica column (80 g)
100% hexane to 100% EtOAc

50% CH3OH:CH2Cl2 (-6)

50% H2O:CH3OH (-7)

5.10 g

8.96 g

Fraction 1
20.2 mg
Fraction 2
26.7 mg
Fraction 3
304 mg
Fraction 4
22.6 mg
Fraction 5
49.9 mg
Fraction 6*
54.5 mg
Fraction 7*
40.7 mg
Fraction 8
22.9 mg
Fraction 9*
19.0 mg
Fraction 10*
6.1 mg
Fraction 11
4.3 mg
Fraction 12
4.7 mg
Fraction 13
9.2 mg
Fraction 14
1.5 mg
Fraction 15
1.5 mg
Fraction 16
0.4 mg

* Indicates fractions that
exhibited antimalarial activity

Fraction 17
13.8 mg
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Didemnum sp.
(LMGSC10-96)
120 g

50% CH3OH:CH2Cl2 (-6)

50% H2O:CH3OH (-7)

12.0 g

16.9 g

Silica column (120 g)
100% hexane to 100% EtOAc

Fraction 1
184 mg
Fraction 2
616 mg
Fraction 3*
177 mg
Fraction 4
78.3 mg
Fraction 5
42.1 mg
Fraction 6*
456 mg
Fraction 7
2.77 g
Fraction 8
3.33 g
Fraction 9
1.32 g

* Indicates fractions that
exhibited antimalarial activity
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dock finger sponge
(PSC08-01)
1.42 kg
50% CH3OH:CH2Cl2 (-6)

50% H2O:CH3OH (-7)

74.3 g

73.5 g

Vial B
7.53 g

Silica column (80 g)
100% hexane to 100% EtOAc

Fraction 1
20.1 mg
Fraction 2
14.4 mg
Fraction 3
751 mg
Fraction 4
97.1 mg
Fraction 5
91.1 mg
Fraction 6
1.15 g
Fraction 7
1.55 g
Fraction 8
1.17 g
Fraction 9
188 mg
Fraction 10
243 mg
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Isodictya setifera
(LMGSC10-108)
120 g

Silica column (80 g)
100% hexane to 100% EtOAc

50% CH3OH:CH2Cl2 (-6)

50% H2O:CH3OH (-7)

7.98 g

12.4 g

Fraction 1

Fraction 2

Fraction 3

Fraction 4

Fraction 5

Fraction 6

Fraction 7*

Fraction 8

Fraction 9*

Fraction 10

Fraction 11

9.2 mg

127 mg

174 mg

132 mg

52.5 mg

49.2 mg

780 mg

3.23 g

575 mg

163 mg

123 mg

C18 column (30 g)
100% H2O to 100% CH3OH

Fraction 1a

Fraction 1b

0.7 mg

468 mg

Fraction 2a

Fraction 2b

27.0 mg

2.7 mg

Fraction 3a

Fraction 3b

6.3 mg

22.3 mg

Fraction 4a

Fraction 4b

5.3 mg

23.2 mg
Fraction 1
1.0 mg
Fraction 2
2.8 mg
Fraction 3
2.5 mg
Fraction 4
1.7 mg
Fraction 5
1.7 mg
Fraction 6
2.5 mg
Fraction 7
2.7 mg
Fraction 8
1.7 mg
Fraction 9
1.2 mg
Fraction 10
0.5 mg
Fraction 11
0.8 mg
Fraction 12
2.5 mg
Fraction 13

* Indicates fractions that
exhibited antimalarial activity

1.4 mg
Fraction 5a

Fraction 5b

1.6 mg

7.1 mg
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C18 column (4.6x250 mm, 5μ)
10% CH3CN:H2O to 100% CH3CN

Appendix B: 1H NMR Spectra

1

H NMR spectrum (400 MHz, CDCl3) of the lipophilic extract (50% CH2Cl2:CH3OH) of the orange-top
sponge with yellow interior (PSC01-53-6)

1

H NMR spectrum (400 MHz, CDCl3) of the lipophilic extract (50% CH2Cl2:CH3OH) of the calcaneus
bryozoan (PSC03-133-6)
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1

H NMR spectrum (400 MHz, CD3OD) of the aqueous extract (50% CH3OH:H2O) of the calcaneus
bryozoan (PSC03-133-7)

1

H NMR spectrum (400 MHz, CDCl3) of the lipophilic extract (50% CH2Cl2:CH3OH) of Isodictya
setifera (LMGSC10-108-6)
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1

H NMR spectrum (400 MHz, CD3OD) of the malaria hit (LMGSC10-108-6-7)

1

H NMR spectrum (400 MHz, CD3OD) of LMGSC10-108-6-7-4b
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2

H NMR spectrum (400 MHz, DMSO-d6) of LMGSC10-108-6-7-4b-11
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Appendix C: Chromatograms

NP MPLC chromatogram (100% hexane to 100% EtOAc) of the lipophilic extract (50%
CH2Cl2:CH3OH) of Didemnum sp. (LMGSC10-96-6)

NP MPLC chromatogram (100% hexane to 100% EtOAc) of the lipophilic extract (50%
CH2Cl2:CH3OH) of dock finger sponge (PSC08-01-6)
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NP MPLC chromatogram (100% hexane to 100% EtOAc) of the lipophilic extract (50%
CH2Cl2:CH3OH) of Isodictya setifera (LMGSC10-108-6)
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RP MPLC chromatograms (100% H2O to 100% CH3CN) of the malaria hit, LMGSC10-108-6-7.
Top: insoluble portion, Bottom: 50% CH3CN:CH3OH extract
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Datafile Name:MSL28.lcd
Sample Name:MSL28
Sample ID:MSL28
mV

psi(x10,000)

2000
1.25

1750
1500

1.00

1250
0.75

1000
750

0.50
500
0.25

250
0

0.00
0.0

2.5

5.0

7.5

10.0

12.5

15.0

17.5

20.0

22.5

25.0

27.5

30.0

32.5

35.0

37.5

40.0

42.5

45.0

47.5

RP HPLC chromatogram (10% CH3CN:H2O to 100% CH3CN) of LMGSC10-108-6-7-4b

LC-MS chromatogram of pure CH3OH

LC-MS chromatogram (10% CH3CN:H2O to 100% CH3CN) of LMGSC10-108-6-7-4b-11
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Appendix D: Bioassay Data

10.0
3.33
1.11
0.370
0.123
0.0412
μg/mL
μg/mL
μg/mL
μg/mL
μg/mL
μg/mL
277
507
846
893
983
995
PSC01-53-6-1a
227
514
780
1095
1067
1221
PSC01-53-6-5a
237
444
694
729
736
815
PSC01-53-6-2b
179
459
698
779
827
782
PSC01-53-6-6b
179
412
586
633
705
741
PSC03-133-6-6
209
482
655
812
937
875
PSC03-133-6-7
158
504
710
823
930
911
PSC03-133-6-9
285
489
757
868
932
891
PSC03-133-6-10
138
405
530
651
751
713
LMGSC10-96-6-3
200
389
588
672
884
911
LMGSC10-96-6-6
247
397
458
411
LMGSC10-108-6-7
32
94
295
556
430
473
457
LMGSC10-108-6-9
35
Malaria (Plasmodium falciparum 3D7) bioassay data for primary and secondary interests. Italics
indicate 50-90% growth inhibition; bold face indicates >90% growth inhibition.

100
33.3
11.1
3.70
1.23
0.412
μg/mL
μg/mL
μg/mL
μg/mL
μg/mL
μg/mL
0.27
1.5264
1.3454
1.3012
1.1822
1.2957
PSC01-53-6-1a
0.1986
1.5998
1.2991
1.3605
1.1974
1.2794
PSC01-53-6-5a
1.5075
1.3882
1.2764
1.2503
1.2001
PSC01-53-6-2b
0.1897
0.2044
1.6218
1.39
1.2767
1.2269
1.1347
PSC01-53-6-6b
1.1254
1.481
1.3479
1.2526
1.2261
PSC03-133-6-6
0.1835
0.2333
1.842
1.3909
1.3228
1.2733
1.1678
PSC03-133-6-7
1.6404
1.3038
1.3072
1.199
1.1874
PSC03-133-6-9
0.1769
1.6332
1.3158
1.3544
1.1983
1.1662
PSC03-133-6-10
0.1733
1.6954
1.4447
1.3872
1.2576
1.1844
LMGSC10-96-6-3
0.2003
0.2257
1.9055
1.3974
1.3815
1.2134
1.1968
LMGSC10-96-6-6
1.7287
1.4501
1.3572
1.3107
1.2751
LMGSC10-108-6-7
0.1816
0.2162
1.6364
1.3816
1.2495
1.2947
1.2533
LMGSC10-108-6-9
Cytotoxicity (A549 cell line) bioassay data for primary and secondary interests. Italics indicate
50-90% growth inhibition; bold face indicates >90% growth inhibition.
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